Engflag

Prorenal

Quick links to important sections

Prorenal

Prorenal_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prorenal

Quick Facts about Prorenal

Property Description
Active ingredient Limaprost alfadex
Form Oral tablet
Pharmacological class Prostaglandin E1 analog, Vasodilator, Platelet aggregation inhibitor
General purpose Improvement of blood flow and microcirculation
Origin Synthetic analog

Prorenal: Defining its Active Ingredient and Pharmaceutical Form

Prorenal is a prescription-only medication supplied in the oral tablet dosage form, containing the sole active ingredient, Limaprost alfadex. This compound is specifically formulated as an inclusion complex of Limaprost with alpha-cyclodextrin, which is crucial for chemical stability and ensuring the medicine is reliably orally bioavailable for systemic absorption. Limaprost acts as a PGE1 analog, indicating its close functional relationship to natural substances that regulate blood flow. This formulation, which emphasizes the compound's stability, has been clinically recognized for its ability to provide systemic delivery via the simple oral route, a key differentiation point from other prostanoids often requiring injection.

What Type of Medicine is Limaprost Alfadex?

Limaprost alfadex is categorized as a synthetic analog of the naturally occurring substance prostaglandin E1 (PGE1), or alprostadil. The drug's formal pharmacological class defines it as a prostaglandin E1 agonist, which positions it functionally as both a potent vasodilator and a platelet aggregation inhibitor. Limaprost's activity in modulating these vascular responses aids in circulatory disorders. This dual mechanism makes the compound a recognized therapeutic option for adult patients facing reduced blood flow.

General Purpose and Core Physiological Action

The general purpose of Prorenal is to manage conditions associated with restricted blood flow through its primary physiological actions. It promotes vasodilation, causing small blood vessels to widen, and simultaneously facilitates the inhibition of platelet aggregation, thereby reducing the tendency of blood components to form clumps. These combined actions lead to a net increase in blood flow and enhanced microcirculation, offering a fundamental benefit for supporting the delivery of oxygen and nutrients to compromised tissues. A typical, neutral use scenario involves improving blood supply to the extremities.

What side effects are possible with Prorenal?

Possible Side Effects and Safety Information

The safety profile of Prorenal is primarily defined by the risk of severe hypocalcemia (very low blood calcium levels), which is a serious and potentially life-threatening adverse reaction.

Serious and Clinically Significant Risks

Official regulatory labeling includes a Boxed Warning to highlight the significantly increased risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD), including those on dialysis. This risk is notably higher for patients also affected by chronic kidney disease-mineral and bone disorder (CKD-MBD).

  • Hypocalcemia: Serious events, including hospitalization, life-threatening outcomes, and death, have been associated with severe hypocalcemia in this high-risk population. Symptoms of hypocalcemia can include seizures, confusion, weakness, tingling, or numbness, and irregular heart rhythms.
  • Timing: The risk for severe hypocalcemia is greatest between Weeks 2 to 5 following each injection, although it typically develops within 2 to 10 weeks of administration.

Common Adverse Reactions

The most frequently reported side effects (classified as common) affect the musculoskeletal system. These adverse reactions are generally non-severe but are well-documented in clinical data and regulatory safety summaries.

System-Organ Class Common Adverse Reactions
Musculoskeletal and Connective Tissue Disorders Back pain, muscle pain, pain in the arms or legs

Safety monitoring notes from regulatory bodies emphasize that patients receiving this medication should be monitored closely for signs and symptoms of hypocalcemia, particularly those with advanced CKD. The clinical presentation of these risks defines the drug's overall safety structure.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes a specific overdose profile for Prorenal, detailing the symptoms, potential complications, and required emergency response measures. The severity of an overdose is primarily defined by the resulting clinical manifestations, which often involve critical effects on major physiological systems.

Overdose with Prorenal may be associated with symptoms that often affect the central nervous system, which could include agitation, profound drowsiness, or even coma. Signs may also involve the cardiovascular system, such as a drop in blood pressure (hypotension) or abnormalities in heart rhythm. A serious complication specifically noted in regulatory documents is the potential for acute renal failure, which underscores the life-threatening nature of the event.

When to Seek Immediate Medical Help

Any suspected overdosage with Prorenal must be treated as a medical emergency. Immediate medical assistance is required if an individual exhibits any signs of severe intoxication, such as significant respiratory depression, seizures, unresponsiveness, or profound cardiovascular symptoms. Regulatory labeling emphasizes that a single accidental ingestion, especially in the pediatric population, may be associated with severe or even fatal poisoning and necessitates urgent care.

Emergency Management

The required management of a Prorenal overdose focuses on the immediate support of vital functions. Healthcare professionals are instructed to initiate supportive care, including maintaining a clear airway and monitoring cardiovascular status and vital signs. Official documents also detail the use of specific treatment measures or antidotes, if applicable, along with procedures for enhancing drug elimination or decontamination as part of the clinical protocol. These critical steps are mandated to prevent or mitigate the potential for life-threatening complications.

Therapeutic Uses of Prorenal

What Prorenal Treats: Main Uses and Benefits

Prorenal (Limaprost alfadex) is commonly used across domains where additional symptomatic support is needed for conditions where symptoms are related to physical discomfort. This medication is relevant for two primary therapeutic domains: managing symptoms associated with Thromboangiitis Obliterans and addressing functional impairment in acquired Lumbar Spinal Canal Stenosis. This approach offers symptomatic relief that helps patients cope more steadily and supports patients during episodes of heightened discomfort.

It is used for managing distressing symptoms such as pain, numbness, and symptoms that interfere with daily functioning, such as intermittent claudication. It is also used to help with severe ischemic pain, the feeling of coldness in the limbs, and symptoms related to skin ulcers. The therapeutic benefit is primarily focused on easing the overall symptom load during symptomatic periods.

“This medication is commonly used when short-term symptomatic assistance is needed to address functional strain.”

Quick Fact: Supportive Relief for Symptoms that Interfere with Function
Primary symptoms addressed: Ischemic pain, cold sensation, symptoms related to skin ulcers, and pain/numbness leading to intermittent claudication.
General therapeutic benefit: Provides support that helps ease the overall symptom burden associated with symptoms related to physical discomfort and helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility for Prorenal: Official Regulatory Information

The eligibility for Prorenal, a specialized vitamin/mineral supplement for renal patients, is defined by specific exclusions and conditional use, as stated in regulatory documents.

Category Regulatory Status
Populations for whom use is allowed Patients with documented nutrient deficiencies associated with Chronic Kidney Disease (CKD) or dialysis.
Populations for whom use is contraindicated Patients with known hypersensitivity to any component (active or inactive). Patients with conditions causing excessive iron accumulation (e.g., hemochromatosis) if the product contains iron.
Condition-specific eligibility rules Use must be determined by a healthcare provider for individuals with liver problems or certain gastrointestinal disorders. Supplementation with calcium should be determined individually to avoid complications like hypercalcemia.
Age-related eligibility rules Pediatric use requires consultation with a healthcare professional, as safety and appropriate dosing may not be fully established for all age groups.
Pregnancy and lactation eligibility Use during pregnancy and while breastfeeding requires consultation with a doctor to weigh individual benefits and risks.

Eligibility is contingent upon a medical assessment to ensure the product's components are appropriate for the patient’s specific health status and CKD stage.

What should I know about interactions with other medicines?

The official interaction profile for Prorenal (Limaprost alfadex) is defined by its antiplatelet activity, which is the sole basis for its primary pharmacodynamic interactions with other products affecting blood clotting. The regulatory classification focuses on combinations requiring close caution and monitoring.

Interaction Scope

  • Medicinal product categories with documented interactions: Anticoagulants, Antiplatelet Agents, Thrombolytic Agents, Over-the-Counter (OTC) Medicines, Dietary Supplements.
  • Specific interacting medicines (if explicitly listed): Warfarin, Heparin, Aspirin (Acetylsalicylic acid).
  • Mechanistic basis of interactions (only if stated in label): Additive pharmacodynamic effect leading to enhanced activity on hemostasis/coagulation.

Resulting Interaction Structure

Interacting Substance Class Official Interaction Statement
Anticoagulants (e.g., Warfarin, Heparin) May accelerate bleeding tendency due to combined effects on coagulation.
Antiplatelet Agents Enhanced antiplatelet activity and increased bleeding risk is documented.
Thrombolytic Agents Co-administration may lead to an enhanced bleeding risk.

No pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters, are formally noted. Regulatory documents advise general awareness regarding co-administration with over-the-counter medicines and dietary supplements, stating they may alter the drug's effects. A specific caution is also noted for patients with a bleeding tendency, as the pharmacodynamic interactions are particularly relevant in this defined population.

Mechanism of Action

Nitrogenous Waste Scavenging and Utilization

This mechanistic domain describes how the drug's keto-analogue components act as metabolic precursors to intercept and utilize excess nitrogenous waste products in the metabolic system. This process, involving transamination, effectively decreases the systemic concentration of nitrogen metabolites, influencing nitrogen balance by converting waste into valuable material.

Essential Amino Acid Supply

This domain centers on the strategic provision of both essential amino acids and their metabolic keto-analogue counterparts, which are vital components of protein synthesis pathways. By ensuring an adequate supply of these building blocks, the mechanism supports protein synthesis, resulting in the maintenance of structural protein mass and tissue function.

Modulating the Metabolic State

The combined action of nitrogen scavenging and amino acid repletion creates a metabolic environment that influences pathways regulating protein and nitrogen turnover. This mechanism contributes to a shift in protein turnover kinetics by facilitating nitrogen utilization, resulting in an altered metabolic equilibrium that reflects reduced nitrogen metabolite levels.

Dosage and Administration Information

How Prorenal is Used: Official Dosing and Administration

Prorenal (Limaprost alfadex) is a prescription medicine formulated exclusively as an oral tablet and must be taken by mouth. The way the medicine is used, including its dosage and frequency, is determined by the condition being managed.

Official Dosing and Schedule

Prorenal is administered in three divided doses per day for both approved uses. The total daily intake of limaprost is determined by the number of 5 mcg tablets taken at each administration time.

Indication Dose Per Administration Total Daily Frequency
Thromboangiitis Obliterans 10 mcg (two 5 mcg tablets) 3 times a day
Acquired Lumbar Spinal Canal Stenosis 5 mcg (one 5 mcg tablet) 3 times a day

Administration Requirements and Use Protocol

Adhering to specific administration instructions ensures the medicine is used correctly.

  • Intake Procedure: The tablet must be taken out of its press-through-package (PTP) immediately before ingestion. This is required to maintain the tablet's integrity due to its high sensitivity to moisture.
  • Missed Dose: If an administration time is missed, do not take two doses together at the subsequent time to catch up.
  • Duration of Use: For managing symptoms related to Acquired Lumbar Spinal Canal Stenosis, the use should not be continued aimlessly. The physician must regularly observe the patient’s symptoms and progress to determine the need for continued therapy.

Recent Clinical Evidence

Research evidence / Overview of studies for Prorenal

Research Evidence for Thromboangiitis Obliterans (TAO)

Research exploring Prorenal for Thromboangiitis Obliterans (TAO) was studied for symptoms related to restricted blood flow, primarily through short-term, randomized controlled trials (RCTs) in adult patients. Studies monitored patient-reported outcomes related to physical discomfort, such as pain and reports of feeling coldness in the extremities. The findings describe patterns observed in the studies over the short observation period. The evidence is limited in scope, as the key trials were conducted predominantly in specific Asian populations, meaning the results apply only to the populations studied. Furthermore, the long-term effects are not fully established regarding the sustained changes in symptoms beyond the limited follow-up durations.

Research Evidence for Lumbar Spinal Canal Stenosis (LSS)

The research for acquired LSS involves a comprehensive structure, including multiple RCTs, Systematic Reviews, and Network Meta-Analyses. Studies research examined a broad population of adult patients with LSS, particularly those reporting neurogenic intermittent claudication (leg symptoms that occur during walking). Studies monitored changes in walking ability and distance, as well as patient-reported outcomes describing perceived discomfort like leg pain and numbness. The data show patterns related to changes in these core functional and subjective symptoms. The research was observed in some studies to focus most clearly on radicular pain and numbness, while the findings were mixed regarding changes in low back pain.

Research Gaps and Study Populations

Research was studied for only defined time intervals, typically lasting six to eight weeks in the core efficacy trials. As a result, limited information for long-term outcomes is available, and the durability of effect is not fully established. Several areas of uncertainty exist because the pivotal trials for both LSS and TAO were conducted mostly in Japanese adult populations, meaning comparative evidence is lacking regarding use in diverse global populations. Additionally, data for certain groups remain insufficient for many other clinical scenarios or complex comorbidity groups.

Frequently Asked Questions (FAQ)

Common questions about Prorenal (FAQ)

Q: How quickly does Prorenal start to work for Lumbar Spinal Canal Stenosis symptoms?

Clinical studies indicate that the active ingredient in Prorenal is rapidly absorbed, and the maximum blood concentration is typically observed in approximately 30 minutes to half an hour. However, symptom improvement in areas like pain and walking ability, as observed in clinical trials, is generally assessed and measured over a period of several weeks of continuous use. It is important to remember that individual responses to medication may vary.

Q: Is Prorenal safe to take while pregnant or breastfeeding?

Official regulatory information indicates the need for caution regarding the use of this medication in women who are pregnant, planning to become pregnant, or are breastfeeding. Due to this regulatory caution, consultation with a healthcare professional is necessary to weigh the individual risks and benefits for use during pregnancy or breastfeeding.

How should Prorenal be stored and disposed of?

How to Store and Dispose of Prorenal

The following requirements outline the official, label-based instructions for the storage and disposal of Prorenal to maintain its quality and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (15 C to 30 C / 59 F to 86 F).
Environment Keep the container tightly closed and protect from moisture and light. Avoid freezing and high heat.
Child Safety Keep this and all drugs out of the reach of children.

Disposal Instructions

To dispose of unused or expired Prorenal, do not flush it down the toilet or pour it into a drain unless specifically instructed by a regulatory body. Consult your pharmacist or local waste disposal company regarding safe medication take-back programs or appropriate disposal methods, which avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagJapan

Equivalent of Prorenal found in:

A-Z Index: